Arrhythmogenic Cardiomyopathy: Pharmacologic Management

Mark S. Link, N. A Mark Estes

Research output: Contribution to journalReview article

Abstract

Pharmacologic management of disease is performed for specific reasons, which include reducing symptoms, preventing disease progression, and preventing mortality. In arrhythmogenic cardiomyopathy (AC), there are no randomized clinical trial data on pharmacologic management, and little data overall on the use of drugs in this condition. This article discusses the role of pharmacology in AC to prevent symptoms, limit progression of disease, and prolong life.

Original languageEnglish (US)
Pages (from-to)293-298
Number of pages6
JournalCardiac Electrophysiology Clinics
Volume3
Issue number2
DOIs
Publication statusPublished - Jun 1 2011

    Fingerprint

Keywords

  • β-Blocker
  • Antiarrhythmic agents
  • Arrhythmogenic right ventricular cardiomyopathy/dysplasia
  • Pharmacologic management
  • Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this